AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), would be added for reimbursement by state-run ...

Enhertu is an antibody-drug conjugate (ADC) designed to treat patients with certain types of breast cancer. Credit: Dikushin Dmitry via Shutterstock. The UK’s National Institute for Health and ...